Skip to Content

Teva Pharmaceutical Industries Ltd ADR TEVA

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Flexibility on the Horizon for Teva's Opioid Settlement Amid Flat Q2 Results

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Teva posted moderate results this quarter, with revenue essentially flat and margins within our expected range. Despite middling sales, the company continued to reduce debt and may receive terms that dampen the severity of its eventual settlement in the opioid litigation. We maintain our fair value estimate of $20 per share and our no-moat rating.

Read Full Analysis

Company Profile

Business Description

Headquartered in Israel, Teva Pharmaceutical is the largest generic drug manufacturer in the world. The company was formed in 1901 and has a portfolio of more than 3,500 medicines--roughly 1 out of 9 generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent slightly over half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending Food and Drug Administration approval.

Contact
5 Basel Street
Petach Tikva, 4951033, Israel
T +972 39148213
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 40,216

Related